Pharmamarketeer

FDA approves Eli Lilly’s Reyvow for treatment of migraine in adults

The US FDA has approved Eli Lily’s oral therapy Reyvow (lasmiditan) for the acute treatment of adults with migraine with or without aura, with Lilly noting that this is ‘the first and only FDA-approved medicine in a new class of serotonin (5-HT)1F receptor agonists’.

read more

Medhc-fases-banner
Advertentie(s)